Judy Lieberman: Stay curious and excited about science.

IF 12.6 1区医学 Q1 IMMUNOLOGY

Journal of Experimental Medicine Pub Date : 2024-09-13 DOI:10.1084/jem.20241556

Montserrat Cols

引用次数: 0

Abstract

Judy Lieberman is a professor of pediatrics and adjunct professor of genetics at Harvard Medical School and an endowed chair in cellular and molecular medicine. Her lab studies cytotoxic T lymphocytes (CTL), key cells in the immune defense against viral infection and cancer, as well as molecular pathways activated by the granzymes, and how RNA interference (RNAi) regulates cell differentiation in health and disease states. We spoke to Judy about advice for early career researchers, how she first become interested in cytotoxic T lymphocytes, and key people who have provided mentorship across her career.

查看原文本刊更多论文

朱迪-利伯曼：对科学保持好奇和兴奋。

朱迪-利伯曼（Judy Lieberman）是哈佛大学医学院儿科教授和遗传学兼职教授，也是细胞与分子医学捐赠讲座教授。她的实验室研究细胞毒性 T 淋巴细胞 (CTL)（抗病毒感染和癌症免疫防御的关键细胞）、颗粒酶激活的分子途径，以及 RNA 干扰 (RNAi) 如何调节健康和疾病状态下的细胞分化。我们采访了朱迪，请她谈谈对职业生涯早期研究人员的建议、她是如何开始对细胞毒性T淋巴细胞感兴趣的，以及在她职业生涯中提供指导的关键人物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Experimental Medicine 医学-免疫学

CiteScore

26.60

自引率

1.30%

发文量

189

审稿时长

3-8 weeks

期刊介绍： Since its establishment in 1896, the Journal of Experimental Medicine (JEM) has steadfastly pursued the publication of enduring and exceptional studies in medical biology. In an era where numerous publishing groups are introducing specialized journals, we recognize the importance of offering a distinguished platform for studies that seamlessly integrate various disciplines within the pathogenesis field. Our unique editorial system, driven by a commitment to exceptional author service, involves two collaborative groups of editors: professional editors with robust scientific backgrounds and full-time practicing scientists. Each paper undergoes evaluation by at least one editor from both groups before external review. Weekly editorial meetings facilitate comprehensive discussions on papers, incorporating external referee comments, and ensure swift decisions without unnecessary demands for extensive revisions. Encompassing human studies and diverse in vivo experimental models of human disease, our focus within medical biology spans genetics, inflammation, immunity, infectious disease, cancer, vascular biology, metabolic disorders, neuroscience, and stem cell biology. We eagerly welcome reports ranging from atomic-level analyses to clinical interventions that unveil new mechanistic insights.